Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

On-monitor to initiate Phase 2 demo in Q1 2023 NEW YORK, Dec. 29, 2022 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a affected individual-focused biopharmaceutical company, these days announced that the…

A digital application and augmented physician rounds reduce postoperative pain and opioid consumption after primary total knee replacement (TKR): a randomized clinical trial | BMC Medicine

Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis.…

UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized COVID-19 Patients

Veru Inc. MIAMI, July 25, 2022 (Globe NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a biopharmaceutical firm concentrated on developing novel medicines for COVID-19 and other viral and ARDS-related ailments and…